Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974432012> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W1974432012 endingPage "2449" @default.
- W1974432012 startingPage "2449" @default.
- W1974432012 abstract "The aim of this study is to describe the incidence and type of liver toxicity seen following liver metastases stereotactic body radiation therapy (SBRT) and the corresponding clinical and dosimetric factors associated with toxicity.Between 2002 and 2009, 81 evaluable patients with liver metastases were treated on 2 prospective studies assessing SBRT, with prescription doses based on the effective liver volume irradiated evaluated. Toxicity was defined as grade ≥2 classic or nonclassic radiation induced liver disease (RILD). Specific toxicity endpoints evaluated were worsening transaminases and albumin levels within 3 months of SBRT.Seventy percent of patients had colorectal carcinoma, 55% had extrahepatic disease, 1 patient had hepatitis B, and 54% had received prior chemotherapy. Baseline transaminases were elevated at Common Terminology Criteria for Adverse Effects, V4.0, grade 1, 2, and 3 levels in 33 (41%), 2 (2%), and 0 (0%) patients. The mean prescription dose was 43 Gy (27.7-60 Gy) in 6 fractions. The mean liver (minus gross tumor volume) dose (MLD) was 16 Gy (3-25.6 Gy) in 6 fractions. No classic or nonclassical ≥grade 2 RILD was observed. Within 3 months of SBRT, 49 (61%) patients had worsening of grade of transaminase and 23 (28%) patients had a reduction in albumin, all transient (majority grade ≤2 toxicity) without subsequent clinical toxicity. Seventeen patients exceeded Quantitative Analysis of Normal Tissue Effects in the Clinic MLD guidelines (≤20 Gy), 13 (76%) of whom had worsening of transaminase grade. On multivariate analysis, worsening of liver enzymes was more likely in patients with higher doses to the spared 700 mL of liver (P = .026), and reduction of albumin was more likely with higher effective liver volume (odds ratio, 1.53 [range, 1.08-2.16]) P = .016).Liver metastases SBRT is safe with a low risk of transient biochemical liver toxicity, more likely in patients with a higher effective liver volume and higher doses to the spared uninvolved liver volume." @default.
- W1974432012 created "2016-06-24" @default.
- W1974432012 creator A5023662450 @default.
- W1974432012 creator A5030744236 @default.
- W1974432012 creator A5046361388 @default.
- W1974432012 creator A5062435700 @default.
- W1974432012 creator A5068634798 @default.
- W1974432012 date "1990-07-01" @default.
- W1974432012 modified "2023-10-14" @default.
- W1974432012 title "Preclinicai safety evaluation of mometasone furoate: a high potency topical anti-inflammatory corticosteroid" @default.
- W1974432012 doi "https://doi.org/10.1016/0014-2999(90)94027-u" @default.
- W1974432012 hasPublicationYear "1990" @default.
- W1974432012 type Work @default.
- W1974432012 sameAs 1974432012 @default.
- W1974432012 citedByCount "1" @default.
- W1974432012 crossrefType "journal-article" @default.
- W1974432012 hasAuthorship W1974432012A5023662450 @default.
- W1974432012 hasAuthorship W1974432012A5030744236 @default.
- W1974432012 hasAuthorship W1974432012A5046361388 @default.
- W1974432012 hasAuthorship W1974432012A5062435700 @default.
- W1974432012 hasAuthorship W1974432012A5068634798 @default.
- W1974432012 hasConcept C126322002 @default.
- W1974432012 hasConcept C160160445 @default.
- W1974432012 hasConcept C181199279 @default.
- W1974432012 hasConcept C185592680 @default.
- W1974432012 hasConcept C197934379 @default.
- W1974432012 hasConcept C2776877979 @default.
- W1974432012 hasConcept C2777075537 @default.
- W1974432012 hasConcept C2777793932 @default.
- W1974432012 hasConcept C2779679107 @default.
- W1974432012 hasConcept C2780567839 @default.
- W1974432012 hasConcept C29730261 @default.
- W1974432012 hasConcept C2992208098 @default.
- W1974432012 hasConcept C512861765 @default.
- W1974432012 hasConcept C55493867 @default.
- W1974432012 hasConcept C71924100 @default.
- W1974432012 hasConcept C90924648 @default.
- W1974432012 hasConceptScore W1974432012C126322002 @default.
- W1974432012 hasConceptScore W1974432012C160160445 @default.
- W1974432012 hasConceptScore W1974432012C181199279 @default.
- W1974432012 hasConceptScore W1974432012C185592680 @default.
- W1974432012 hasConceptScore W1974432012C197934379 @default.
- W1974432012 hasConceptScore W1974432012C2776877979 @default.
- W1974432012 hasConceptScore W1974432012C2777075537 @default.
- W1974432012 hasConceptScore W1974432012C2777793932 @default.
- W1974432012 hasConceptScore W1974432012C2779679107 @default.
- W1974432012 hasConceptScore W1974432012C2780567839 @default.
- W1974432012 hasConceptScore W1974432012C29730261 @default.
- W1974432012 hasConceptScore W1974432012C2992208098 @default.
- W1974432012 hasConceptScore W1974432012C512861765 @default.
- W1974432012 hasConceptScore W1974432012C55493867 @default.
- W1974432012 hasConceptScore W1974432012C71924100 @default.
- W1974432012 hasConceptScore W1974432012C90924648 @default.
- W1974432012 hasIssue "6" @default.
- W1974432012 hasLocation W19744320121 @default.
- W1974432012 hasOpenAccess W1974432012 @default.
- W1974432012 hasPrimaryLocation W19744320121 @default.
- W1974432012 hasRelatedWork W1832604137 @default.
- W1974432012 hasRelatedWork W1980386903 @default.
- W1974432012 hasRelatedWork W2020987875 @default.
- W1974432012 hasRelatedWork W2042430160 @default.
- W1974432012 hasRelatedWork W2051976808 @default.
- W1974432012 hasRelatedWork W2372320496 @default.
- W1974432012 hasRelatedWork W2558360119 @default.
- W1974432012 hasRelatedWork W307921490 @default.
- W1974432012 hasRelatedWork W4207054562 @default.
- W1974432012 hasRelatedWork W4281879243 @default.
- W1974432012 hasVolume "183" @default.
- W1974432012 isParatext "false" @default.
- W1974432012 isRetracted "false" @default.
- W1974432012 magId "1974432012" @default.
- W1974432012 workType "article" @default.